Full video transcriptClick to expand
Auto-generated transcript of @futurethemonster's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Look at this mansion look at my bitch. You look in the space look at the diamond look at the wrist
- 0:06Look at the dancer look at the money look at them dollars and dollars a stack
GLP-1 weight loss claims on TikTok: what the data says
Quick answer
This video contains no health claims related to GLP-1 receptor agonists or any other medical topic. The transcript is rap lyric content referencing wealth and does not address semaglutide, tirzepatide, weight management, or diabetes treatment in any form. Clinical context cannot be derived from the transcript and any GLP-1 categorization of this video appears to be a tagging or algorithmic error.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 weight loss claims on TikTok: what the data says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 weight loss claims on TikTok: what the data says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 weight loss claims on TikTok: what the data says" from futurethemonster. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video contains no health claims related to GLP-1 receptor agonists or any other medical topic.
The reason this review is not generic is the source wording and the canonical claim label "glp1 lost ya mind future future futurehendrix infuturewetrust." In this clip, the useful excerpt is: "Look at this mansion look at my bitch." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
This video contains no health claims related to GLP-1 receptor agonists or any other medical topic.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video contains no health claims related to GLP-1 receptor agonists or any other medical topic. The transcript is rap lyric content referencing wealth and does not address semaglutide, tirzepatide, weight management, or diabetes treatment in any form. Clinical context cannot be derived from the transcript and any GLP-1 categorization of this video appears to be a tagging or algorithmic error.
- This video contains zero health claims. It is rap music categorized under GLP-1 content, which appears to be a metadata or algorithmic error.
- The STEP 1 trial (Wilding et al., 2021, NEJM) found semaglutide 2.4mg produced approximately 14.9% average body weight reduction over 68 weeks in adults with obesity.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- This video contains zero health claims. It is rap music categorized under GLP-1 content, which appears to be a metadata or algorithmic error.
- The STEP 1 trial (Wilding et al., 2021, NEJM) found semaglutide 2.4mg produced approximately 14.9% average body weight reduction over 68 weeks in adults with obesity.
- The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) found tirzepatide achieved up to 22.5% mean weight reduction, the highest recorded in a phase 3 obesity pharmacotherapy trial at that time.
- The SELECT trial (Lincoff et al., 2023, NEJM) found semaglutide reduced major adverse cardiovascular events by 20% in high-risk patients with obesity, extending clinical rationale beyond weight loss alone.
- GLP-1 medications are FDA-regulated prescription drugs, not wellness products. Compounded versions are not FDA-approved and are not equivalent to brand-name formulations like Ozempic or Wegovy.
- Common side effects of GLP-1 agonists include nausea, vomiting, and constipation. Rare but serious risks include pancreatitis and gastroparesis. Medical supervision is required.
- Aspirational wealth content algorithmically tagged as health content can shape how patients perceive medical treatments. That is a platform responsibility issue worth monitoring.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @futurethemonster actually say?
Nothing about GLP-1 medications. Not a single word. The transcript is a rap verse, almost certainly from Future's catalog, referencing mansions, jewelry, dancers, and stacked cash. Lyrics like "look at the diamond look at the wrist" and "look at them dollars and dollars a stack" are flex rap, full stop. There is no medical claim here, no health advice, and no mention of semaglutide, tirzepatide, weight loss, or anything adjacent to telehealth. This video was tagged under GLP-1 content, but the content itself contains zero relevant health information.
Does the science back this up?
There is no scientific claim to evaluate. The video makes no assertions about physiology, pharmacology, or metabolic health. Since we cannot fact-check a lyric about wrist diamonds against a clinical trial, we will use this space to cover what GLP-1 science actually looks like in 2024, so you have a baseline when content in this category does make real claims.
GLP-1 receptor agonists work by mimicking the glucagon-like peptide-1 hormone, which stimulates insulin secretion, suppresses glucagon, and slows gastric emptying. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found tirzepatide produced mean weight reductions of up to 22.5% in adults with obesity. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4mg achieved roughly 14.9% average body weight reduction versus placebo. These are not trivial numbers. They represent the most significant pharmacological weight loss data published in decades.
What did they get wrong (or right)?
The creator got nothing wrong about GLP-1 drugs because they said nothing about GLP-1 drugs. That is not a compliment. It means this video was miscategorized, mislabeled, or incorrectly surfaced under health content. That is a platform-level problem, not a creator problem.
What is worth flagging: when rap or celebrity content gets pulled into health content categories algorithmically, viewers who are genuinely researching weight loss medications may encounter it and draw their own connections. The association between wealth signaling and body transformation narratives is real in popular culture. A viewer primed to research GLP-1s who lands on aspirational flex content could, in some contexts, reinforce a mindset that these medications are a luxury product rather than a medical intervention. That framing has consequences. It is not this creator's fault, but it is worth naming.
What should you actually know?
If you landed here looking for real information about GLP-1 medications, here is the short version. Semaglutide and tirzepatide are FDA-approved medications prescribed by licensed clinicians. They are not lifestyle supplements. They are not interchangeable with each other or with compounded versions. The SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) confirmed that semaglutide 2.4mg reduced major cardiovascular events by 20% in adults with obesity and established cardiovascular disease, independent of weight loss. That is a meaningful finding that extends the clinical rationale beyond aesthetics.
Common side effects include nausea, vomiting, constipation, and in some cases more serious outcomes like pancreatitis or gastroparesis, though rates of severe adverse events in trials were low. Anyone considering these medications should do so under medical supervision, with regular follow-up, and with realistic expectations about what the drugs do and do not do long-term.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
futurethemonster · TikTok creator
202.2K views on this video
Lost ya mind - Future 🦅 #future #futurehendrix #infuturewetrust
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about this video contains zero health claims. it?
This video contains zero health claims. It is rap music categorized under GLP-1 content, which appears to be a metadata or algorithmic error.
What does the video say about the step 1 trial (wilding et al., 2021, nejm) found?
The STEP 1 trial (Wilding et al., 2021, NEJM) found semaglutide 2.4mg produced approximately 14.9% average body weight reduction over 68 weeks in adults with obesity.
What does the video say about the surmount-1 trial (jastreboff et al., 2022, nejm) found tirzepatide?
The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) found tirzepatide achieved up to 22.5% mean weight reduction, the highest recorded in a phase 3 obesity pharmacotherapy trial at that time.
What does the video say about the select trial (lincoff et al., 2023, nejm) found semaglutide?
The SELECT trial (Lincoff et al., 2023, NEJM) found semaglutide reduced major adverse cardiovascular events by 20% in high-risk patients with obesity, extending clinical rationale beyond weight loss alone.
What does the video say about glp-1 medications?
GLP-1 medications are FDA-regulated prescription drugs, not wellness products. Compounded versions are not FDA-approved and are not equivalent to brand-name formulations like Ozempic or Wegovy.
What does the video say about common side effects of glp-1 agonists include nausea, vomiting,?
Common side effects of GLP-1 agonists include nausea, vomiting, and constipation. Rare but serious risks include pancreatitis and gastroparesis. Medical supervision is required.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by futurethemonster, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.